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Chronic granulomatous disease (CGD), a primary immunodeficiency characterized by a deficient neutrophil oxidative burst and
the inadequate killing of microbes, is well known to cause a significantly increased risk of invasive infection. However, infectious
complications are not the sole manifestations of CGD; substantial additional morbidity is driven by noninfectious complications
also. These complications can include, for example, a wide range of inflammatory diseases that affect the gastrointestinal tract, lung,
skin, and genitourinary tract and overt autoimmune disease. These diseases can occur at any age and are especially problematic in
adolescents and adults with CGD. Many of these noninfectious complications present a highly challenging therapeutic conundrum,
wherein immunosuppression must be balanced against an already markedly increased risk of invasive fungal and bacterial infections. In this review, the myriad noninfectious complications of CGD are discussed, as are important gaps in our understanding of
these processes, which warrant further investigation.

The seemingly contradictory association between primary
immunodeficiencies and autoimmune disease is well known
[1], and many of the noninfectious complications of chronic
granulomatous disease (CGD) exemplify this paradox [2]. In
this review, we discuss the remarkable variety of inflammatory
conditions that are associated with the CGD phenotype. Many
of these disease manifestations result in conundrums for treating physicians, and we discuss the challenges in diagnosis and
optimal management of such conditions.
GASTROINTESTINAL MANIFESTATIONS OF CGD

Granulomatous colitis seems to be the most common inflammatory complication of CGD in children, and more than 40%
of patients with X-linked CGD ultimately develop some form of
inflammatory bowel disease (IBD) [3]. In a series of children with
CGD followed at the National Institutes of Health (NIH), gastrointestinal (GI) involvement was identified in 46 (32.8%) of 140
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[4]. The median age of GI symptom presentation was 5 years, and
most symptoms present in the first decade of life. In a contemporary cohort maintained by the US Immunodeficiency Network
(USIDNET), 38% of patients experienced inflammatory GI complications (Supplementary Table 1). GI manifestations of CGD can
precede the onset of infectious symptoms and can mimic symptoms of IBD, particularly Crohn disease [4]. Misdiagnosis of CGD
colitis as ulcerative colitis or Crohn disease can delay the diagnosis
of CGD significantly and can be life-threatening, because the treatment for IBD often involves immunosuppressant agents, which
confer significant risk for infectious complications in patients with
CGD. In addition, GI complications in patients with a known CGD
diagnosis can cause significant morbidity, including detrimental
effects on growth, nutritional status, and wound healing [4].
The spectrum of GI symptoms in patients with CGD can
be broad and nonspecific, including abdominal pain, diarrhea,
weight loss, fever, and nausea. Other features can include rectal
bleeding, weight loss, perianal abscesses, bowel obstructions,
fistulae, and strictures [5]. Any portion of the GI tract can be
involved, although the colon is affected most often; distal disease that involves the rectum and anus (eg, perianal fistulae,
rectal strictures) are particularly common [5]. In addition, large
granulomas in the gut can lead to obstruction (including gastric outlet obstruction), which can occur anywhere throughout
the GI tract, from the rectum to the esophagus [6]. Severe GI
involvement occurs more commonly in patients with X-linked
CGD [4, 7] than in those with autosomal recessive (AR) disease.
Endoscopic evaluation and tissue biopsy are of critical importance in characterizing GI findings in patients with

CGD. Colitis that involves the rectum and anus is seen most
commonly with endoscopic evaluation, although the upper GI
tract is often involved, and skip lesions can be found throughout
the GI tract [8]. Histopathologic changes found in GI biopsy
specimens from patients with CGD include the presence of
local inflammation and granulomas, which sometimes are
indistinguishable from findings in patients with Crohn disease. However, characteristic findings that can distinguish CGD
enteritis from Crohn disease do exist. Pigment-laden macrophages within the lamina propria, tissue eosinophilia, and
sharply defined histiocyte aggregates in granulomata have been
associated with CGD [5, 9]. Staining for CD68, a monocyte and
macrophage marker, revealed significantly fewer CD68+ cells in
biopsy specimens from patients with CGD than in those from
patients with Crohn disease [9] and might be useful in the diagnosis of CGD-associated enteral disease.
IBD is often classified according to age at disease onset.
Patients diagnosed with IBD before they are 6 years of age
are classified as having very-early-onset IBD and might represent a subset of patients with a particularly severe IBD
disease course and decreased responsiveness to the anti-inflammatory and immunomodulatory therapies conventionally used for the treatment of IBD. These patients, especially
those diagnosed before 2 years of age, represent a population
of patients with a relatively higher incidence of underlying
immune deficiency. Evaluation for CGD and other immune
deficiencies should be considered in this population, which
might represent an opportunity for the early diagnosis of
CGD, because GI symptoms can be the initial presenting
symptoms of CGD.
The treatment of CGD-associated colitis and other GI
manifestations in patients with CGD represents a therapeutic
dilemma. The mainstay of therapy for IBD includes immunosuppressive regimens, which often include corticosteroids and
tumor necrosis factor (TNF) inhibition. Such regimens pose
a serious potential risk in patients with CGD, particularly
for those with an invasive fungal disease such as Aspergillus
infection. CGD-associated enteritis or colitis management
often requires a combination of luminal anti-inflammatory therapy (eg, mesalamine) and low-dose corticosteroids.
Antimetabolites, such as methotrexate or azathioprine (while
the patient remains on optimal antimicrobial prophylaxis), are
also helpful for recurrent cases. TNF-blocking biologic agents
have been associated with severe infections and death and are
generally contraindicated [10]. Prolonged corticosteroid use in
patients with CGD colitis can be associated also with invasive
superinfection [11]. In patients with CGD that is complicated
by severe GI inflammation, hematopoietic stem cell transplantation is often considered, because it is curative for CGD and
related GI manifestations [12] (see also Connelly et al, this
supplement).

INFLAMMATORY LUNG DISEASE IN PATIENTS WITH
CGD

With optimal preventive care and management of infectious
complications, patients with CGD now routinely live to adulthood. Increasing evidence now exists to suggest that certain
inflammatory complications of CGD can become more prominent as patients age, and pulmonary disease drives much of the
morbidity in this population. Current estimates indicate that
at least half of all patients with CGD will develop pulmonary
manifestations of CGD in their lifetime, particularly during
adulthood [7, 13–17]. Although infectious pulmonary diseases
such as pneumonia and lung abscesses are more common than
noninfectious pulmonary lesions in patients with CGD, inflammatory complications can have profound effects on CGDassociated morbidity and treatment [15]. These noninfectious
respiratory processes seem to be inflammatory in nature, which
is consistent with the known chronic dysregulated inflammation associated with CGD [16, 18, 19]. These inflammatory
respiratory events can occur independently from or concomitantly with or be triggered by an infection [16, 17, 20, 21].
The epidemiology and prevalence of noninfectious pulmonary manifestations in patients with CGD are unclear. Patients
with X-linked CGD seem to have a higher risk of developing
inflammatory episodes than do their counterparts with AR
CGD [17, 22]. In a retrospective single-center French study
of 98 patients with CGD (median age, 13.5 years), the prevalence of respiratory disease was reported to be 26.4%, and it
accounted for 8.6% of all inflammatory events recorded [22].
A more recent retrospective study, which drew from the same
cohort, found that noninfectious pulmonary events occurred in
28% of the 67 adult patients included in the study [17]. Data
from USIDNET indicate that a wide variety of potential sinopulmonary complications of CGD can occur (Supplementary
Table 2), including interstitial lung disease, pulmonary nodules,
pleural effusions, and chronic obstructive pulmonary disease.
A common presentation for noninfectious events in patients
with CGD is granuloma formation, with or without concurrent lymphocytic infiltrate [16, 17]. Lung granulomas can present with obstructive symptoms, depending on their location
in the pulmonary tree [23]. These masses have been termed
“autoimmune granulomas,” because they typically resolve with
immunomodulatory therapy [2]. Granulomas are often sterile,
although it can be difficult to exclude the presence of an infectious agent despite negative laboratory evaluation results [16].
Radiologic pulmonary findings are often nonspecific and
can reveal consolidation, ground-glass or tree-in-bud opacities,
scattered nodules, and bronchiectasis [17, 24, 25]. The radiographic appearance of CGD-associated pulmonary lesions
can mimic neoplasm of the lung. CGD, therefore, should be
included in the differential diagnosis when abnormal radiologic findings, such as granulomas or masses, are found on
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chest imaging to minimize diagnostic delay and/or inappropriate therapy [26–28]. Pathologic findings of CGD-associated
inflammatory lung disease are also variable. In the French adult
cohort described previously, circumscribed nodules or parenchymal consolidation occurred after a respiratory infection
in 7 of 11 patients (6 of 7 after Aspergillus infection), which
might indicate a dysregulated response to infection. Biopsy
results often reveal granulomas, with or without neutrophilic or
eosinophilic microabscesses. Other biopsy findings can include
increased reticular or ground-glass opacities without previous
evidence of infection [17].
The diagnosis and treatment of inflammatory pulmonary disease in patients with CGD are unique challenges. Bronchoscopy
with endobronchial biopsy, percutaneous needle biopsy, or
open lung biopsy are often indicated to secure a microbiologic
diagnosis, although the failure to isolate an organism does not
prove the lack of an infectious etiology. When inflammatory
disease is strongly suspected, the use of immunomodulators,
such as corticosteroids, thalidomide, hydroxychloroquine, and
methotrexate, has been found to resolve consolidation but not
interstitial lung disease [17]. Some experts recommend short
pulses of corticosteroid therapy escalating to additional agents
such as methotrexate if a patient’s response to steroids is poor,
and the patient should remain on optimal CGD prophylaxis
throughout that time. The optimal management of these pulmonary complications, however, remains unknown.
Mulch pneumonitis is a specific concern for patients with
CGD and has even been reported as the sentinel manifestation
of CGD [29]. This syndrome presents with acute-onset hypoxia,
dyspnea, fever, and bilateral infiltrates 1 to 10 days after inhalation of fungal spores and hyphae (typically Aspergillus spp), such
as those that can be found in mulch, hay, peat moss, or dirt [21].
The clinical and radiographic findings can overlap with other
hypersensitivity pneumonitis syndromes (eg, farmer’s lung).
Appropriate treatment for mulch pneumonitis with both glucocorticoids and antifungal agents must be initiated in a timely
manner to minimize morbidity and risk of death [21, 29].
AUTOIMMUNE/RHEUMATOLOGIC DISEASE IN PATI
ENTS WITH CGD

Although a clear association between X-linked CGD carrier status and increased risk of autoimmunity exists (see “Inflammatory
Disease in Carriers of X-Linked CGD”), so too does a burden of
autoimmune disease in patients with CGD. Study of a national
registry of more than 350 patients found that patients with CGD
might meet diagnostic criteria for systemic lupus erythematosus
(SLE) (0.5% of patients) or discoid lupus erythematosus (DLE)
(2.7% of patients) [7]. These rates are substantially higher than
those reported for the general US population (2.9 per 100 000
with SLE, 4.2 per 100 000 with DLE) [30]. The increased risk of
autoimmunity can be seen across geographies and age ranges,
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with a focus on syndromes that resemble lupus, rheumatoid
arthritis, and immunoglobulin A (IgA) nephropathy [6]. In a
Turkish cohort [31], approximately half of the patients had an
autoimmune or autoinflammatory disease (including IBD, stomatitis/gingivitis, reactive arthritis, idiopathic thrombocytopenia [ITP], pericardial effusion, and autoimmune hepatitis). In
a French cohort of patients with CGD who reached adulthood,
17% reported at least one autoimmune condition, although the
range of autoimmune processes noted was wide and included
cold agglutinin disease, IgA nephropathy, acute demyelinating
encephalitis, and antiphospholipid syndrome [32]. In a cohort
of European patients, 6% were noted to have autoimmune
complications; the most common was discoid lupus (18 [4%]
of 429), followed by 2 cases of rheumatoid arthritis and 1 case
each of SLE, dermatomyositis, sacroiliitis, ITP, and autoimmune
hepatitis [15]. In the CGD registry maintained by the NIH, 10%
of the patients had an autoimmune complication beyond IBD
[33]. Additional reported rheumatologic conditions in patients
with CGD include Raynaud phenomenon [34], lymphadenopathy, stomatitis [35], and aphthous ulcers with cutaneous lesions
that mimic Behçet disease [36]. Patients with CGD also seem
to be at increased risk of developing hemophagocytic lymphohistiocytosis [37]. In the USIDNET registry (summarized in
Supplementary Table 3), 25 patients (4.9%) carried at least 1
autoimmune diagnosis, and the most common were SLE (21.2%
of those with an autoimmune diagnosis) and DLE (15.2% of
those with an autoimmune diagnosis). With regard to therapy,
it has been noted that fully treating an autoimmune condition
when identified in a patient with CGD is important. Although
patients with CGD ideally will not require more than low-dose
prednisone for their autoimmune disease, and immunosuppression clearly should be minimized as much as possible, it
is important to treat these complications fully, which includes
considering the use of high-dose steroids or immunosuppressing steroid-sparing regimens, should they be necessary [2]. Of
course, in such scenarios, it is important also to clinically monitor patients closely.
NONINFECTIOUS AND INFLAMMATORY COMPLICAT
IONS OF CGD IN OTHER SYSTEMS (GENITOURINARY,
OCULAR, AND CUTANEOUS)
Genitourinary Complications

Inflammatory complications of CGD can lead to complications
in the genitourinary (GU) tract by the formation of large granulomas that lead to obstruction or stricture at various locations
[7, 38], and these complications occur much more commonly
in patients with CGD than in the general population [39]. An
analysis of the USIDNET cohort performed for this review indicated that GU complications occurred in 16.1% of the patients
(Supplementary Table 4), and of them, 16.8% of such complications were obstructive. In a European cohort of more than

400 patients with CGD, 6% were noted to have an obstruction
in their GU system [15]. In a French cohort, 12 (12%) of 98
patients experienced inflammatory GU symptoms [22]. In
addition, an increased incidence of eosinophilic cystitis has
been noted in patients with CGD, perhaps more frequently in
those with X-linked disease [31, 40–43]. Although this condition is often treated with a prolonged course of steroids, some
experts recommend using oral antihistamines and intravesical
steroids [31].
Ocular Complications

Inflammatory complications of CGD can be seen in the eye,
although less commonly than in other organ systems. In a US
registry, 8 (2%) of 368 patients had chorioretinitis [6], and in
a European registry, 8 of 429 patients had chorioretinitis [15].
In a French cohort, 6 (6%) of 98 patients had ocular complications that ranged from chorioretinitis and ocular granuloma to
uveitis [22].
Dermatologic Complications

In a large cohort of patients with CGD who reached adulthood,
13.4% reported cutaneous inflammatory events [32], more
commonly after 16 years of age. A similar French cohort had
an ~10% prevalence of skin complications, including granulomatous acne, inflammatory nodular lesions, and photosensitivity [22]. In addition, aphthous stomatitis and cutaneous
lymphocytic infiltration [44] have been noted in association
with CGD [34]. The contemporary USIDNET cohort includes
120 (23%) patients with a dermatologic inflammatory diagnosis (Supplementary Table 5), most commonly acne and eczema.
Treatment with topical immunosuppressive therapy, and systemic therapy only when needed, is indicated [32].
CGD also has been associated with increased risks of wound
dehiscence, poor wound healing [45], and pyoderma gangrenosum in patients after surgery [46]. A small (n = 10) pediatric
study found a 30% rate of impaired wound healing [47], and in
a separate cohort of patients who required colonic surgery, a
13% dehiscence rate was found [48]. In the cohort of patients
with CGD maintained by the NIH, patients with X-linked CGD
were more likely to require surgery, and wound complications
occurred in 10% of the patients [46]. It should be noted that
wound dehiscence in the setting of CGD seems to be atypical in
that corticosteroids might speed healing [46].
INFLAMMATORY DISEASE IN CARRIERS OF X-LINKED
CGD

X-chromosome inactivation (XCI) is thought to occur early
in embryogenesis and leads to random epigenetic silencing of
either the maternal or paternal X chromosome and expression
of a single X chromosome (ie, lyonization) in females [49].
Female carriers of mutations in CYBB, which encodes gp91phox,

are usually clinically unaffected because they have sufficient
numbers of phagocytes expressing wild-type CYBB and thus
have adequate superoxide production to protect against typical CGD infections. Some carriers, however, have nonrandom
XCI, in which wild-type CYBB is silenced, which leads to markedly reduced oxidase activity. They can develop mild to severe
infectious or inflammatory manifestations, including severe
IBD [50–53]. In addition, females might have progressive XCI
skewing with aging, and previously healthy carriers can develop
manifestations of CGD later in life [54]. Interesting to note is
that the risk of autoimmune or inflammatory disease in carriers
is not clearly correlated with baseline oxidative burst function,
unlike the risk of infection [55].
Dysregulated inflammation partly underlies the various
degrees of pathology in different organs that X-linked carriers
of CYBB mutations can exhibit [55–57]. Chorioretinitis was
observed in 10% of carrier females in 1 small series of patients
and their female carrier relatives [58]. Dermatologic manifestations in carriers include DLE, eczema, folliculitis, and photosensitivity [59–62]. GI manifestations include abdominal
pain, intermittent diarrhea, IBD, and colon polyposis [62–64].
Autoimmune manifestations, including polyarthritis, recurrent aphthous ulcers, and Reynaud phenomenon, have been
reported to be more prevalent in carriers than in a healthy
control population [59–62]. The presence of symptoms consistent with SLE in CGD carriers is correlated with lower neutrophil oxidative burst function than in carriers without SLE
symptoms [55].
FRONTIERS AND FUTURE DIRECTIONS

The origin of dysregulated and poorly controlled inflammation
in patients with CGD remains somewhat mysterious [65–68].
Many factors can play a role, and a number of theories have
been proposed, including the presence of persistent antigen
(including smoldering infection [22]) leading to attempted
immunologic control via granuloma formation, alterations in
key inflammatory pathways (including the inflammasome),
alterations in the balance of CD4+ T-helper cell subsets
[31, 69], and impaired clearance of chemotactic factors [45].
More recently, there has been a focus on the effect of CGD on
apoptosis [33]. Evidence exists to indicate that neutrophils with
a defective nicotinamide adenine dinucleotide phosphate oxidase complex (NOX2) are resistant to apoptosis in vitro and
produce fewer anti-inflammatory mediators after phagocytosing apoptotic targets [70]. In addition, in mouse models of
X-linked CGD, injection of apoptotic gp91-knockout neutrophils can lead to autoantibody formation [71]. Also, a role for
altered production of neutrophil extracellular traps, wherein
absent or altered NOX2 can alter inflammatory pathways [72],
has been proposed. In addition, it has been noted that neutrophils from patients with CGD are less able to engage the DNA
Noninfectious Complications of CGD • JPIDS 2018:7 (Suppl 1) • S21

damage-repair process properly when they are stimulated using
strategies that generate reactive oxygen species and generate
more inflammatory cytokines [73].
With a focus on novel therapeutics, both monocytes and
macrophages from patients with CGD have revealed decreases
in efferocytosis [74, 75]. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, restored efferocytosis in vitro, and 2 patients who received the drug for other
clinical reasons experienced improved monocyte efferocytosis and improved reactive oxygen species production [75]. It
is interesting to note also that a number of candidate genes
are associated with disease severity in patients with CGD
[33], and recent work has linked variants in myeloperoxidase
and FcgRIIIb genes with GI complications and autoimmune
disease with mannose-binding lectin and FcgRIIa polymorphisms [76]; additional studies of the genotype–phenotype link in patients with CGD might be illuminating for
inflammatory and infectious phenotypes and for therapeutic
options (ie, prophylaxis and response to hematopoietic stem
cell transplantation conditioning strategies).
Despite advances in medical management of CGD, these
important gaps in our understanding of CGD immunopathogenesis remain obstacles to maximizing outcomes for patients.
For example, pulmonary involvement remains an important cause of death in this patient population [20]. As patients
survive longer, the short- and long-term cumulative effects of
repetitive infectious and noninfectious respiratory disorders
gain importance [16]. Baseline respiratory burst function correlates with risk of infection, but whether the development of
autoimmune or inflammatory complications are similarly correlated remains unclear. In addition, because most noninfectious pulmonary complications occur in adulthood, it would be
highly beneficial to identify biomarkers and/or predictors that
help us to risk-stratify patients before the development of overt
pulmonary signs and symptoms. The development of large clinical registries of patients with a primary immunodeficiency
might prove useful in this regard.
No specific evidence-based guidelines regarding the monitoring and management of noninfectious complications of
patients with CGD currently exist, which underscores an
important knowledge gap that requires future research. With
respect to pulmonary complications, 1 group proposed computed tomography of the chest every 2 years with specific pulmonary evaluation once per year and chest radiography and
pulmonary function tests performed more frequently as part
of routine monitoring; the risk/benefit ratio of this monitoring
scheme is uncertain [17]. One important question that remains
unanswered is whether aggressive antimicrobial prophylaxis
and treatment affect the development of noninfectious respiratory manifestations, especially because infections can serve as
triggers or occur concomitantly.
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The growing body of evidence suggests that carriers of
X-linked CGD indeed have an increased risk of clinically significant disease, and further investigation is warranted to better characterize and address such findings. It is notable that the
risk of inflammatory disease in carriers does not seem to correlate with oxidative burst function. It also remains unclear if
carriers of CGD might be protected from the development of
atherosclerotic disease as patients with CGD seem to be [77].
An additional challenge is how to identify asymptomatic carriers, especially if no affected males are in the family. A prospective study screened 120 pediatric patients with IBD using
a dihydrorhodamine flow cytometry assay but failed to identify
any patients or carriers [78]. This relatively small study highlights the inherent challenges of detecting a relative rare disease
even when a test with good sensitivity and specificity is available and the target population is selected appropriately. Last,
no evidence-based guidelines are currently available for the
short- and long-term management of carriers. Some authors
have proposed that trimethoprim-sulfamethoxazole prophylaxis be initiated in carriers when respiratory burst function
falls to ≤20%, regardless of the presence of symptoms [57]. The
optimal management of carriers with autoimmune or inflammatory manifestations remains to be elucidated, and a better
understanding of outcomes in these patients in research studies
and clinical trials of those with IBD, SLE, and other relevant
diseases is needed.
CONCLUSIONS

Noninfectious complications of CGD are clearly associated with
all mutations leading to a defective nicotinamide adenine dinucleotide phosphate oxidase complex, and even the X-linked carrier state of CGD. Inflammatory complications are seen more
often in patients with X-linked CGD than in those with AR
CGD [22], and the patterns and frequencies of these complications vary across body systems. Overall, inflammatory events
begin later in life in patients with CGD than do infections [32],
and they create a particular challenge for the management of
CGD, particularly in adolescent and adult patients.
The treatment of inflammatory disease in patients with
CGD requires a difficult balance between therapeutic immunosuppression and the augmented risk of severe infection.
Collaboration with subspecialists relevant to the organ systems
affected is a critical component of management. Further significant work in the field is needed to decipher the mechanisms
that drive this increased risk of inflammatory disease and to
guide the optimal management of these challenging conditions.
Supplementary Data
Supplementary materials are available at Journal of the Pediatric Infectious
Diseases Society online.
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